Can calcitonin gene-related peptide monoclonal antibody improve migraine and restless legs syndrome?
Source : https://www.jns-journal.com/article/S0022-510X(22)00324-0/fulltext
A significant association between migraine and restless legs syndrome (RLS) has been reported, and their coexistence is not uncommon. We report a patient with concomitant migraine and RLS who showed improvement of both migraine and RLS symptoms after treatment with galcanezumab, a calcitonin gene-related peptide (CGRP) monoclonal antibody.
Conclusions: We report a case of improvement of both migraine and RLS after treatment with CGRP monoclonal antibody. Additional studies are needed to clarify how CGRP antagonism affects RLS symptoms in patients with migraine and RLS comorbidity.
• Source: Journal of the Neurological Sciences
• Conclusion: “We report a case of improvement of both migraine and RLS [restless legs syndrome] after treatment with CGRP monoclonal antibody. Additional studies are needed to clarify how CGRP antagonism affects RLS symptoms in patients with migraine and RLS comorbidity.”
• In the current case, a 47-year-old woman who has a history of being treated for migraine without aura with dopamine agonists and α2δ ligands experienced recent worsening of migraine and RLS symptoms. She was therefore started on the CGRP monoclonal antibody galcanezumab.
• After 1 month of treatment, the number of headache days reduced from 20 to 4, and her score on the International RLS Study Group Rating Scale improved. Additionally, photo/phono/osmo-phobia improved. This clinical improvement was observed at 5 months.
• The effect of CGRP monoclonal antibody on RLS remains to be elucidated.